Skip to main content

About your Search

20130106
20130114
Search Results 0 to 0 of about 1
and you can't have those unless you're involved early in science. we developed models where we are integrated into the ecosystems around the world. i was at stanford this morning where the biggest life sciences employer in boston, we have a strong hub in china and in europe. and we are really trying to develop a collaborative open innovative concept. what we put in has to have a strong proof of concept. on vaccines, on drugs that have a clear benefit over existing therapies. because the bar just gets higher and higher from reimbursement authorities every year. >> sure. and does that include transactions -- more transactions in terms of mna? you know, some of your growth has come through acquisitions. going forward in the next three years, does that growth continue to come through acquisitions or organic? >> i think it's going to be more organic. i'll tell you. in our industry, everybody's got a lot of cash. everybody is interested in growing inorganically. it's tough to find deals that have value. because sanofi now grows we have less than 3% subject to small molecule patents e
Search Results 0 to 0 of about 1